Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508819-23-00

Acronym

2022-523-GLOB1

Enrollment

Registered

2024-06-05

Start date

2024-07-24

Completion date

2025-05-19

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary immune thrombocytopenia (ITP)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Norway, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026